Thursday 7 May, 2026
Introduction Drug-induced QT prolongation is a serious side effect where certain medications delay heart muscle recharging, risking a fatal, rapid,…
Read morePoster: Drug/Disease Modelling - Safety
CONCENTRATION-QTC ANALYSIS OF TOVORAFENIB IN PATIENTS WITH RAF-ALTERED, RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA, ADVANCED SOLID TUMORS AND MELANOMA
Thursday 7 May, 2026
Introduction: Genetic alterations and dysregulation of the mitogen-activated protein kinase (MAPK) pathway have been found in many different types of…
Read moreIntegrated In Vitro/In Silico Systems Immunology Model to Quantify Drug-Induced Changes in the Immune Response after Influenza A Virus Infection – A Blueprint for the Preclinical Assessment and Clinical Translation of Infection Risks for Biologics
Thursday 16 October, 2025
Objectives: Biological modalities, such as antibody-based biologics, have revolutionized the treatment of many neoplastic and inflammatory diseases over the last years….
Read morePopulation pharmacokinetics of intravenous MIT-001 in healthy subjects and patients
Thursday 16 October, 2025
Objectives: MIT-001 is a potent mitochondrial-targeting antioxidant targeting various inflammatory diseases. Utilizing pharmacokinetic (PK) and safety data from previous clinical…
Read moreA streamlined, semi-automated workflow allows quick and efficient QTc and other ECG intervals modeling assessment, saving time and cost.
Thursday 16 October, 2025
Introduction All drugs with systemic bioavailability need assessment of the QT interval which represents ventricular repolarization activity of the heart…
Read morePopulation pharmacokinetic-pharmacodynamic modeling of the iclepertin drug effect on hemoglobin levels
Thursday 16 October, 2025
Introduction: Iclepertin (BI 425809) is a novel, potent and selective glycine transporter-1 (GlyT1) inhibitor currently in Phase III development to…
Read morePharmacometric analysis of symptom burden during anti-cancer drug therapy by a Markov modelling approach
Thursday 16 October, 2025
Introduction: Adverse drug events (ADE) represent a great burden for patients in the treatment with antitumor drugs and can in…
Read morePopulation pharmacokinetics of ticagrelor and active metabolite during veno-arterial extracorporeal membrane oxygenation
Thursday 16 October, 2025
Objective: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a mechanical method for supporting the cardiopulmonary systems usually used for treating cardiac…
Read morePopulation pharmacokinetics of FM101 in healthy volunteers and long-term safety prediction: phase 1 study
Thursday 16 October, 2025
Introduction/Objectives: Non-alcoholic steatohepatitis is a chronic liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Currently, there are no approved…
Read moreA model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC
Thursday 16 October, 2025
Introduction: Immune checkpoint inhibitors (ICIs) have become a landmark therapy over recent years benefitting from their remarkable clinical efficacy in…
Read more